Intellia Therapeutics Inc. (NTLA)
Shareholder Rights Advocates at Levi & Korsinsky Investigate Intellia Therapeutics, Inc. (NTLA) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic priorities and key anticipated 2025 milestones".
Intellia Therapeutics: Buying The Path To Commercialization
Intellia Therapeutics, Inc. is undergoing strategic reorganization, halting NTLA-3001, and reducing workforce by 27% to extend cash runway into 2027, focusing on late-stage programs NTLA-2002 and Nexiguran Ziclumeran. Despite industry headwinds and significant layoffs, I see Intellia's cost-cutting measures as prudent, aiming for commercialization of NTLA-2001 and NTLA-2002 in large, promising markets. The gene therapy sector faces turmoil, with multiple companies making tough decisions; however, Intellia's focus on late-stage programs may position it for future growth and potential M&A interest.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA). Investors who purchased Intellia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NTLA.
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
On Thursday, Intellia Therapeutics Inc NTLA outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z.
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down
Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by 27%.
Intellia Crashes 60% in a Year: How Should You Play the Stock?
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy.
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Intellia initiated the Phase 3 HAELO trial for NTLA-2002, targeting lifelong control of hereditary angioedema (HAE) with a single-dose CRISPR-based therapy. Positive Phase 2 NTLA-2002 data showed most patients remained attack-free; however, limitations like small sample size and short follow-up require cautious interpretation. Phase 1 data for nexiguran ziclumeran (nex-z) in ATTR amyloidosis showed disease stabilization, but competitive therapies demonstrate more robust improvements.
Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the stage for a modest rally. While last month's drop is appropriately discounting NTLA-2002, investors should be encouraged that 3 Phase III trials will be engaged by year-end, representing multiple opportunities for substantial upside. Intellia's financial position is robust with $945 million in cash, enough to fund operations into late 2026.
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.
Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Lina Li - Senior Director of Investor Relations and Corporate Communications John Leonard - President & Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President & Chief Scientific Officer Ed Dulac - Executive Vice President & Chief Financial Officer Conference Call Participants Rick Bienkowski - Cantor Fitzgerald Yanan Zhu - Wells Fargo Securities Joseph Thome - TD Cowen Maury Raycroft - Jefferies Dae Gon Ha - Stifel Jay Olson - Oppenheimer Silvan Tuerkcan - Citizens JMP William Pickering - Bernstein Operator Good morning and welcome to Intellia Therapeutics' Third Quarter 2024 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
